Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ori Biotech has developed a proprietary automated cell and gene therapy manufacturing platform aimed at making advanced therapies more scalable, affordable, and accessible. The IRO® system automates and standardizes the production process from preclinical through commercial scale. As a technology/platform provider rather than a therapeutic developer, Ori does not have its own clinical results or pipeline but supports partners across the cell/gene therapy field. The company raised over $100 million in Series B funding in January 2022 to support transition from pre-commercialization toward market launch.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ori Biotech.